The panel discussion will examine the complexity of diabetes and its management, as well as the potential of gene and cell therapies. During the panel, Dr. Jaiman, a pediatric endocrinologist, highlight the promise of cell replacement therapy to reduce the need for ongoing management of type 1 diabetes and improve patients’ quality of life and comorbidities.
“Regular insulin administration remains the standard for treating patients with type 1 diabetes, which puts a significant strain on disease management and affects quality of life,” said Dr. Jaiman. “Regenerative medical approaches for type 1 diabetes using stem cell-derived islet cell replacement therapy are advancing from discovery to clinical trials and have the potential to reduce the need for ongoing management of the disease through a functional cure.”
At ViaCyte, Dr. Jaiman insists on advancing the development of stem cell therapy programs in the diabetes field to change the paradigm of healthcare for patients with type 1 diabetes. To learn more about the potential of islet cell replacement therapy to achieve the long-awaited functional cure for type 1 diabetes, read Dr. Jaiman’s article on the general mass Brigham innovation Blog.
With two decades of experience, ViaCyte has two clinical-stage product candidates – PEC-Encap and PEC-Direct – that are actively recruiting type 1 diabetes patients for two phase 2 clinical trials. The data is expected in the second half of 2021 for PEC-Encap and in the first half of 2022 for PEC-Direct. The submission of license applications for biologics is expected to be submitted in 2024 and 2025, respectively.
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies made from pluripotent stem cells and medical device systems for encapsulating and implanting cells. ViaCyte has the ability to use any technology individually or together to address critical human diseases and disorders that may be treated by replacing lost or defective cells or proteins. The company’s first product candidates are being developed as potential long-term treatments for type 1 diabetes patients to achieve glucose control goals and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand the company’s efforts, ViaCyte has partnered with leading companies including CRISPR Therapeutics and WL Gore & Associates. ViaCyte is headquartered in San Diego, California. More information is available at www.viacyte.com. Connect with ViaCyte on Twitter, Facebook and LinkedIn.
Via the World Medical Innovation Forum
Hosted by Maj. Brigham, the World Medical Innovation Forum is a global gathering of more than 1,700 high-level healthcare leaders. It responds to the increasing transformation of healthcare and its impact on innovation. The forum is based on the belief that regardless of the magnitude of this change, the center of health care must be a shared, fundamental commitment to collaborative innovation – industry and science work together to improve patients’ lives. More information is available at https://worldmedicalinnovation.org.
SOURCE ViaCyte, Inc.